

CANIGEN CHPPI/L LYOPHILISATE AND SUSPENSION FOR SUSPENSION FOR INJECTION FOR DOGS

Authorised

- Canine adenovirus 2, strain Manhattan, Live
- Canine parainfluenza virus, strain Manhattan, Live
- Canine parvovirus, strain Cornell 780916, Live
- Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated
- Leptospira interrogans, serovar Canicola, strain 601903, Inactivated
- Canine distemper virus, strain Lederle, Live

Product identification

Medicine name:

CANIGEN CHPPI/L LYOPHILISATE AND SUSPENSION FOR SUSPENSION FOR INJECTION FOR DOGS

Active substance:

Canine adenovirus 2, strain Manhattan, Live

Canine parainfluenza virus, strain Manhattan, Live

Canine parvovirus, strain Cornell 780916, Live

Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated

Leptospira interrogans, serovar Canicola, strain 601903, Inactivated

Canine distemper virus, strain Lederle, Live

Target species:

Dog

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Canine adenovirus 2, strain Manhattan, Live

10000.00 50% cell culture infectious dose / 1.00 Dose

Canine parainfluenza virus, strain Manhattan, Live

100000.00 50% cell culture infectious dose / 1.00 Dose

Canine parvovirus, strain Cornell 780916, Live

100000.00 50% cell culture infectious dose / 1.00 Dose

Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated

4250.00 enzyme-linked immunosorbent assay unit / 1.00 Dose

Leptospira interrogans, serovar Canicola, strain 601903, Inactivated

4350.00 enzyme-linked immunosorbent assay unit / 1.00 Dose

Canine distemper virus, strain Lederle, Live

1000.00 50% cell culture infectious dose / 1.00 Dose

Pharmaceutical form:

Lyophilisate and suspension for suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AI02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Belgium

Available in:

Belgium

Package description:

1 vial of lyophilisate and 1 vial of suspension

100 vials of lyophilisate and 100 vials of suspension

50 vials of lyophilisate and 50 vials of suspension

25 vials of lyophilisate and 25 vials of suspension

10 vials of lyophilisate and 10 vials of suspension

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Virbac

Marketing authorisation date:

3/08/2016

Manufacturing sites for batch release:

Virbac

Responsible authority:

Federal Agency For Medicines And Health Products

Authorisation number:

BE-V500337

Date of authorisation status change:

3/08/2016

Reference member state:

France

Procedure number:FR/V/0237/001

Concerned member states:

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland
Germany Greece Hungary Ireland Italy Latvia Lithuania Luxembourg
Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain
Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents

eu-puar-frv0237001-mr-rpe312-en.pdf